NEW YORK (GenomeWeb News) – The German biotech company Kinaxo Biotechnologies, a spinout of the Max Planck Institute, and Bayer Vital announced today that they have formed a collaboration to identify novel phosphoproteomics biomarkers for predicting cancer treatment outcomes.

The researchers plan to use Kinaxo's quantitative phosphoproteomics technology, PhosphoScout, to find and quantify phosphorylation sites as part of a clinical trial conducted by Bayer Vital on the use of oral anti-cancer drug sorafenib (Nexavar) in acute myeloid leukemia.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.